Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
7 hedge funds and large institutions have $34.9K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
2.58% less ownership
Funds ownership: 2.58% → 0% (-2.6%)
25% less capital invested
Capital invested by funds: $46.7K → $34.9K (-$11.8K)
36% less funds holding
Funds holding: 11 → 7 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$135K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$28.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.03K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$514 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$15.5K |
| 2 |
HF
HRT Financial
New York
|
-$9K |
| 3 |
VF
Virtu Financial
New York
|
-$9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.77K |
| 5 |
Morgan Stanley
New York
|
-$190 |
VRPX Hedge Fund Activity: Q1 2025 in Review
7 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q1 2025, worth a combined $34.9K — down 25% from $46.7K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VRPX and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $135K. The largest seller was Geode Capital Management, exiting entirely with an estimated $15.5K sold.
- 7 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q1 2025, down from 11 in Q4 2024.
- Funds reported $34.9K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q1 2025, down 25% quarter-over-quarter.
- 1 fund opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q1 2025 and 5 closed out, a net change of -4 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q1 2025 was Millennium Management, an estimated $135K added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q1 2025 was Geode Capital Management, an estimated $15.5K sold.
Based on aggregated 13F filings for Q1 2025.